Welcome to our dedicated page for Indivior Pharmaceuticals SEC filings (Ticker: INDV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Indivior PLC (NASDAQ: INDV) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a pharmaceutical issuer focused on opioid use disorder (OUD) treatments, Indivior uses its filings to report financial results, strategic initiatives, governance changes, and key legal and regulatory matters.
Investors can review Form 8-K current reports in which Indivior details material events such as quarterly financial results, updates on the Indivior Action Agenda, restructuring charges, optimization of its Rest of World business, and changes to executive compensation or board composition. Other 8-K items describe the company’s intent to redomicile from the U.K. to Delaware, shareholder approvals of a scheme of arrangement and amended articles of association, and the conclusion of a legacy U.S. Department of Justice resolution agreement.
Through its periodic reports (Forms 10-K and 10-Q, when available on EDGAR), readers can examine segment performance, revenue composition, R&D spending, and risk factors related to Indivior’s OUD-focused portfolio, including SUBLOCADE, SUBOXONE Film, PERSERIS, and OPVEE. These filings also typically include detailed discussions of non-GAAP measures such as adjusted EBITDA and non-GAAP operating expenses, along with reconciliations to U.S. GAAP metrics.
Stock Titan enhances these documents with AI-powered summaries that highlight the most important points in lengthy filings, helping users quickly understand changes in guidance, restructuring actions, legal exposures, or capital structure. Real-time updates from EDGAR mean that new Indivior filings, including any future proxy statements on executive compensation and Form 4 insider transaction reports, are surfaced promptly.
By using this page, investors, analysts, and other stakeholders can efficiently navigate Indivior’s SEC reporting history, monitor developments in its OUD pharmaceutical business, and interpret the financial and governance implications of its regulatory disclosures.
Indivior PLC director David E. Wheadon reported acquiring additional ordinary shares of the company. On 01/05/2026, he obtained 1,771 ordinary shares at a price of $35.3926 per share, bringing his directly held stake to 14,395 shares after the transaction.
According to the disclosure, these shares were acquired through his participation in a Non-Executive Director Purchase Plan, under which he receives a portion of his director fees in stock instead of cash.
Indivior PLC director reports existing share ownership. A Form 3 filing shows that director Ryan Barbara beneficially owns 1,188 ordinary shares of Indivior PLC, held directly. This filing is an initial disclosure of holdings rather than a new purchase or sale, giving investors a baseline view of this director’s equity stake in the company.
Indivior plc director Daniel A. Ninivaggi filed an initial ownership report showing beneficial ownership of 16,148 Ordinary Shares of Indivior plc. These shares are reported as held directly by the director. The filing date of the ownership event is listed as 01/01/2026, and no derivative securities are reported in the derivative securities table.
Indivior plc director Kingsley Stuart A filed an initial ownership report showing a modest personal stake in the company. As of January 1, 2026, he beneficially owned 920 ordinary shares, held directly. The filing indicates no derivative securities such as options or warrants. The document also references a power of attorney authorizing Jordan Saltzberg to sign on the reporting person's behalf.
Indivior plc director Juliet Thompson reported her initial ownership of the company’s ordinary shares. She holds 3,850 ordinary shares directly and an additional 5,775 ordinary shares indirectly through her spouse, reflecting her total beneficial stake as of the reported event date. The filing is an initial statement of beneficial ownership and does not reflect a new purchase or sale, but rather discloses Thompson’s existing holdings in connection with her role as a director.
Indivior PLC director Mark Stejbach has filed an initial beneficial ownership report showing his equity stake in the company. As of January 1, 2026, he beneficially owned 16,072 Ordinary Shares of Indivior PLC, held directly. This filing is a Form 3, which establishes his starting share position as a director and does not reflect a new purchase or sale, only his reported holdings on that date.
Indivior PLC filed an initial insider ownership report for Chief Executive Officer and director Joseph Ciaffoni. The filing shows he directly owns 56,000 ordinary shares. It also lists equity awards giving him rights to additional shares in the future.
Ciaffoni holds 1,266,903 performance stock units, each representing a contingent right to one ordinary share at an exercise price of $0. These units were granted on May 13, 2025 and may vest based on achieving specific volume weighted average price per share targets over any 30 consecutive trading days on or after May 8, 2026, with vesting tranches tied to VWAP levels from $15.00 to $35.00. He also holds 422,302 restricted stock units, granted on May 13, 2025, each convertible into one ordinary share at $0 and scheduled to vest in a single installment on May 8, 2028.
Indivior plc director David E. Wheadon has filed an initial Form 3 disclosing his ownership in the company. As of 01/01/2026, he beneficially owns 12,624 Ordinary Shares of Indivior plc, held directly. The filing lists no derivative securities such as options or warrants. The form is filed by a single reporting person, and the signature block references a Power of Attorney authorizing the signing of the report.
Indivior PLC’s chief financial officer Ryan Preblick has filed an initial Form 3 disclosing his equity holdings in the company. He beneficially owns 280,582 ordinary shares directly. In addition, he holds restricted stock units that each represent a contingent right to receive one ordinary share of Indivior PLC.
One grant covers 6,302 restricted stock units that were awarded on March 14, 2024 and vest in a single installment on March 14, 2026. A second grant covers 70,459 restricted stock units that were awarded on March 7, 2025 and vest in a single installment on March 7, 2028. All positions are reported as directly owned, and the filing also includes a power of attorney authorizing the signatory to sign on his behalf.
Indivior plc director Keith Humphreys filed an initial statement of beneficial ownership, reporting that he directly owns 5,027 Ordinary Shares of Indivior plc as of 01/01/2026. The filing shows only non-derivative holdings, with no derivative securities such as options or warrants listed in the derivative securities table.